Cullinan Reports $356M Cash, Runway Into 2029; Key Data Readouts Ahead
CGEM has more than doubled off its 52-week low of $5.68.
Summary
Cullinan's Q2 update extends cash runway into 2029 with $356M on hand, easing near-term financing concerns. The company laid out a dense catalyst calendar: CLN-978 multi-dose RA data in Q3 2026, SLE data in Q4 2026, and Phase 2 starts in early 2027. Velinotamig SLE data also due Q4 2026, with a Phase 1/2 basket study in autoimmune cytopenias starting early 2027. In oncology, a potentially registrational Phase 2 for CLN-049 in AML begins this quarter following a positive FDA meeting. This follows positive Phase 1 data across the pipeline in recent months, and the cash position removes a key overhang.
At the time of this announcement, CGEM was trading at $17.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.68 to $19.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.